Transfection reagents facilitate the transfer of nucleic acids into cells enabling downstream analysis and are used for gene expression, protein production and silencing studies. As a result transfection reagents find applications across various therapeutic areas from oncology to infectious diseases. These reagents help insert genetic material, from DNA plasmids and siRNA to CRISPR/Cas9 components, into cells allowing scientists to interrogate gene function, produce therapeutic proteins, or correct genetic mutations.
The global transfection reagents and equipment market is estimated to be valued at US$ 1342.78 Bn in 2024 and is expected to exhibit a CAGR of 8.4% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Advancements including CRISPR/Cas9 have increased nucleic acid applications in functional genomics and disease modeling. Non-viral reagents are gaining popularity over viral vectors owing to their lower risk of immunogenicity and toxicity. Lipid-based transfection methods dominate the market as they yield high transient transfection rates. However, bionic polyplexes combine features of lipoplexes and polyplexes to improve nucleic acid delivery efficiency. With growing emphasis on personalized medicine, induced pluripotent stem cells are becoming a lucrative area for transfection. Several companies are developing novel hydrogel and nanoparticle formulations for safe and targeted nucleic acid delivery in the cells and tissues.
Porter’s Analysis
Threat of new entrants: The threat of new entrants is moderate. While there are no major entry barriers in terms of raw materials or customers, significant capital is required for research and development which makes entry difficult for small players.
Bargaining power of buyers: The bargaining power of buyers is high as the market has several large pharmaceutical companies that buy transfection reagents in bulk. Buyers can negotiate for better prices and demand high quality standards.
Bargaining power of suppliers: The bargaining power of suppliers is moderate. While a few major players dominate the supply market, suppliers of raw materials have low bargaining power given the availability of substitute materials.
Threat of new substitutes: The threat of new substitutes is moderate. While alternative transfection methods are available, reagents provide ease of use and high transfection efficiencies. Significant R&D is required in developing new substitutes.
Competitive rivalry: The market has some large players and medium sized local players resulting in high competitive rivalry. Players compete based on price, product quality, and innovation.
Key Takeaways
The global Transfection Reagents and Equipment market size is expected to witness high growth. The global transfection reagents and equipment market is estimated to be valued at US$ 1342.78 Bn in 2024 and is expected to exhibit a CAGR of 8.4% over the forecast period 2024 to 2031.
North America currently dominates the market due to presence of major players and growing biotechnology industry in the region. The Asia Pacific market is expected to grow at fastest pace during the forecast period supported by rising biomedical research and increasing outsourcing activities to China and India.
Key players operating in the Transfection Reagents and Equipment market are Nestle Waters, PepsiCo, Inc., The Coca-Cola Company. These key players are focusing on new product launches and strategic collaborations to strengthen market presence. For instance, in 2022 PepsiCo, Inc. launched antimicrobial Pepsi bottles made from recycled plastic materials.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it